Immutep LtdASX: IMM

Positive Update on IMP761 Phase 1

· Issued by Immutep Ltd

Filed with ASX · · 2 pages · English

Summary by 6ix AI

The study observed a dose-dependent immunosuppressive effect and significant reduction in T cell activity, suggesting potential efficacy in treating autoimmune conditions. The trial will continue as planned, with further updates expected in the first half of the following year, including data presentation at a major medical conference.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Immutep Ltd on 6ix

Earlier from Immutep

Later from Immutep

All Immutep news releases